EW
Edwards Lifesciences Corporation · Healthcare · Medical - Devices
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 14.87M | $1.28B | n/a | n/a |
| Q2 2026 | 165 | -6 | 426.19M | $38.48B | +2 | −7 |
| Q1 2026 | 173 | +2 | 408.99M | $32.75B | +6 | −5 |
| Q4 2025 | 170 | 0 | 441.50M | $37.63B | +2 | −1 |
| Q3 2025 | 24 | -1 | 280.60M | $21.82B | +1 | −3 |
| Q2 2025 | 23 | 0 | 232.09M | $18.15B | n/a | n/a |
| Q1 2025 | 20 | -1 | 112.98M | $8.18B | n/a | −1 |
| Q4 2024 | 21 | +1 | 116.40M | $8.61B | +1 | n/a |
| Q3 2024 | 19 | +1 | 77.58M | $5.12B | +2 | −1 |
| Q2 2024 | 18 | n/a | 60.09M | $5.55B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 16.92M | n/a | $1.56B | 0.3% | n/c | 1 | SEC ↗ ×9 |
| 2 | Geode Capital Management ✦ (passive) | 13.24M | n/a | $1.22B | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 3 | Norges Bank ✦ (passive) | 8.54M | n/a | $788.63M | 0.1% | n/c | 1 | SEC ↗ |
| 4 | Fisher Asset Management ✦ | 8.27M | n/a | $764.05M | 0.3% | n/c | 1 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 7.34M | n/a | $677.60M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 6 | PRIMECAP Management ✦ | 1.81M | n/a | $167.28M | 0.1% | n/c | 1 | SEC ↗ |
| 7 | Adage Capital Partners ✦ | 649.66K | n/a | $60.01M | 0.1% | n/c | 1 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 624.40K | n/a | $57.68M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 9 | Millennium Management ✦ | 524.21K | n/a | $48.42M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Bridgewater Associates ✦ | 519.81K | n/a | $48.02M | 0.3% | n/c | 1 | SEC ↗ |
| 11 | Point72 Asset Management ✦ | 444.16K | n/a | $41.03M | 0.1% | n/c | 1 | SEC ↗ |
| 12 | Baillie Gifford ✦ | 352.30K | n/a | $32.54M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 13 | AQR Capital Management ✦ | 309.12K | n/a | $28.55M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 14 | Arrowstreet Capital ✦ | 225.02K | n/a | $20.79M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Two Sigma Investments ✦ | 152.01K | n/a | $14.04M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | D. E. Shaw & Co. ✦ | 89.65K | n/a | $8.28M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 17 | Marshall Wace ✦ | 74.67K | n/a | $6.90M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Gotham Asset Management ✦ | 11.86K | n/a | $1.10M | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 4 holders, 229.24K shares, $319,498 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 619 sh · $53,017
Officer · 619 sh · $54,169
Officer · 544 sh · $49,534
Officer · 2.64K sh · $237,907
Officer · 1.24K sh · $113,417
Officer · 1.15K sh · $105,893
Officer · 30.65K sh · $2.79M
Officer · 619 sh · $56,967
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology